These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36980191)

  • 1. Validation of an ICH Q2 Compliant Flow Cytometry-Based Assay for the Assessment of the Inhibitory Potential of Mesenchymal Stromal Cells on T Cell Proliferation.
    Piede N; Bremm M; Farken A; Pfeffermann LM; Cappel C; Bonig H; Fingerhut T; Puth L; Vogelsang K; Peinelt A; Marschalek R; Müller M; Bader P; Kuçi Z; Kuçi S; Huenecke S
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stem/stromal cell quality control: validation of mixed lymphocyte reaction assay using flow cytometry according to ICH Q2(R1).
    Nicotra T; Desnos A; Halimi J; Antonot H; Reppel L; Belmas T; Freton A; Stranieri F; Mebarki M; Larghero J; Cras A; Faivre L
    Stem Cell Res Ther; 2020 Oct; 11(1):426. PubMed ID: 33004063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A streamlined proliferation assay using mixed lymphocytes for evaluation of human mesenchymal stem cell immunomodulation activity.
    Herzig MC; Delavan CP; Jensen KJ; Cantu C; Montgomery RK; Christy BA; Cap AP; Bynum JA
    J Immunol Methods; 2021 Jan; 488():112915. PubMed ID: 33212091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro.
    Conforti A; Scarsella M; Starc N; Giorda E; Biagini S; Proia A; Carsetti R; Locatelli F; Bernardo ME
    Stem Cells Dev; 2014 Nov; 23(21):2591-9. PubMed ID: 24937591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of human mesenchymal stromal cells with peripheral blood mononuclear cells in a Mitogenic proliferation assay.
    Herzig MC; Christy BA; Montgomery RK; Delavan CP; Jensen KJ; Lovelace SE; Cantu C; Salgado CL; Cap AP; Bynum JA
    J Immunol Methods; 2021 May; 492():113000. PubMed ID: 33609532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells.
    Guan Q; Li Y; Shpiruk T; Bhagwat S; Wall DA
    Cytotherapy; 2018 May; 20(5):639-649. PubMed ID: 29548707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction.
    Prevosto C; Zancolli M; Canevali P; Zocchi MR; Poggi A
    Haematologica; 2007 Jul; 92(7):881-8. PubMed ID: 17606437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
    Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G.
    Nasef A; Mathieu N; Chapel A; Frick J; François S; Mazurier C; Boutarfa A; Bouchet S; Gorin NC; Thierry D; Fouillard L
    Transplantation; 2007 Jul; 84(2):231-7. PubMed ID: 17667815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological properties of umbilical cord blood-derived mesenchymal stromal cells.
    Oh W; Kim DS; Yang YS; Lee JK
    Cell Immunol; 2008 Feb; 251(2):116-23. PubMed ID: 18495100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats.
    Xia X; Chen W; Ma T; Xu G; Liu H; Liang C; Bai X; Zhang Y; He Y; Liang T
    Liver Transpl; 2012 Jun; 18(6):696-706. PubMed ID: 22344929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6.
    Najar M; Rouas R; Raicevic G; Boufker HI; Lewalle P; Meuleman N; Bron D; Toungouz M; Martiat P; Lagneaux L
    Cytotherapy; 2009; 11(5):570-83. PubMed ID: 19565371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nature vs. Nurture: Defining the Effects of Mesenchymal Stromal Cell Isolation and Culture Conditions on Resiliency to Palmitate Challenge.
    Boland LK; Burand AJ; Boyt DT; Dobroski H; Di L; Liszewski JN; Schrodt MV; Frazer MK; Santillan DA; Ankrum JA
    Front Immunol; 2019; 10():1080. PubMed ID: 31134100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The suppressive effect of mesenchymal stromal cells on T cell proliferation is conserved in old age.
    Landgraf K; Brunauer R; Lepperdinger G; Grubeck-Loebenstein B
    Transpl Immunol; 2011 Sep; 25(2-3):167-72. PubMed ID: 21726642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases.
    Mebarki M; Iglicki N; Marigny C; Abadie C; Nicolet C; Churlaud G; Maheux C; Boucher H; Monsel A; Menasché P; Larghero J; Faivre L; Cras A
    Stem Cell Res Ther; 2021 Nov; 12(1):571. PubMed ID: 34774107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease.
    Tobin LM; Healy ME; English K; Mahon BP
    Clin Exp Immunol; 2013 May; 172(2):333-48. PubMed ID: 23574329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy.
    Haack-Sorensen M; Friis T; Bindslev L; Mortensen S; Johnsen HE; Kastrup J
    Scand J Clin Lab Invest; 2008; 68(3):192-203. PubMed ID: 17852829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunosuppressive properties of non-cultured dermal-derived mesenchymal stromal cells and the control of graft-versus-host disease.
    Gao L; Liu F; Tan L; Liu T; Chen Z; Shi C
    Biomaterials; 2014 Apr; 35(11):3582-8. PubMed ID: 24468404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions.
    Najar M; Raicevic G; Id Boufker H; Stamatopoulos B; De Bruyn C; Meuleman N; Bron D; Toungouz M; Lagneaux L
    Exp Hematol; 2010 Oct; 38(10):922-32. PubMed ID: 20570633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
    Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.